Shifting Focus in Autoimmune Diseases

Rob Armstrong, CEO of Artax Biopharma, discussed the evolving landscape of R&D in autoimmune diseases, highlighting the shift from oral drugs to protein therapeutics and now to oral versions of biologics. Artax’s initial trial in psoriasis, using the first-in-class mechanism NC5K, showed promising results. Armstrong emphasized the importance of empowering teams and fostering diversity in communication styles. He noted the industry's trend towards developing small molecules to complement existing therapies. Concerns were raised about the impact of changes at NIH, FDA, and drug pricing on innovation, with a focus on maintaining a supportive environment for scientific advancement.

Highlights from the episode include:

• Armstrong highlights Artax’s focus on moving into other autoimmune diseases like rheumatoid arthritis and atopic dermatitis.
• An explanation for the shift from oral drugs with many side effects to protein therapeutics, which have been more selective and effective.
• The challenges of translating animal models to human therapeutics and the importance of seeing biomarker movement and clinical endpoints within four weeks.
• The importance of empowering the entire team to speak up, be creative, and aggressive in their ideas.
• Armstrong highlights the need to recognize different ways of communication and thinking within the team.